Effects of a transdermal testosterone metered-dose nanoemulsion in peri- and postmenopausal women: a novel protocol for treating low libido

• Autor(a) principal: Botelho,Marco Antonio
• Data de Publicação: 2015
• Outros Autores: Queiroz,Dinalva Brito, Carvalho,Celso Felício, Freitas,Allan, Barros,Gisele, Gouvea,Julia, Patrus,Lia, Bannet,Mariane, Rego,Amália Cinthia, Araújo-Filho,Irami, Silva,Ivaldo
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: MedicalExpress (São Paulo. Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2358-04292015000500003
• topic: androgen deficiency; menopause; nanotechnology; transdermal delivery; testosterone; nanoparticles

OBJECTIVE: To investigate the efficacy of a transdermal nanoemulsion testosterone associated with transdermal estrogen therapy as a novel protocol treatment for emergent loss of libido. METHODS: Twenty-four women, aged 31-75 years (mean age, 51.7), with emergent loss of libido were allocated to treatment with a novel transdermal formulation of 500 µg/day of testosterone (Biolipid/B2®-testosterone) for 12 weeks, as part of an open label prospective study on peri- and post-menopausal women. Subjects applied the formulation on the right forearm. Clinical and laboratorial parameters including the sexual complaints; serum concentrations of testosterone, insulin, C-reactive protein, weight, blood pressure; body mass index and waist circumference were compared between baseline and 12 weeks after treatment. RESULTS: The mean total serum testosterone increased significantly (p = 0.009) after 12 weeks of treatment. No adverse or androgenic events were observed. There were positive and significant differences (p < 0.05) on sexual complaints, blood pressure, body mass index and waist circumference after transdermal nanoemulsion testosterone treatment. CONCLUSION: This protocol is effective in increasing testosterone levels in peri- and postmenopausal women with low libido.